



NATIONAL GUIDELINE CLEARINGHOUSE™ (NGC) GUIDELINE SYNTHESIS

SCREENING FOR COLORECTAL CANCER

Guidelines

1. American Gastroenterological Association, American Society for Gastrointestinal Endoscopy, American College of Physicians, American College of Gastroenterology (AGA/ASGE/ACP/ACG). [Colorectal cancer screening and surveillance: clinical guidelines and rationale-update based on new evidence](#). Gastroenterology 2003 Feb; 124(2): 544-60. [102 references]
2. Finnish Medical Society Duodecim (FMS). [Prevention and screening of colorectal cancer](#). Helsinki, Finland: Duodecim Medical Publications Ltd.; 2005 Feb 23. Various p.
3. University of Michigan Health System (UMHS). [Adult preventive health care: cancer screening](#). Ann Arbor (MI): University of Michigan Health System; 2004 May. 12 p. [4 references]
4. U.S. Preventive Services Task Force (USPSTF). [Screening for colorectal cancer: recommendations and rationale](#). Ann Intern Med 2002 Jul; 137(2): 129-31 [31 references].

TABLE OF CONTENTS:

[INTRODUCTION](#)

[TABLE 1: SCOPE](#)

[TABLE 2: COMPARISON OF RECOMMENDATIONS FOR SCREENING FOR COLORECTAL CANCER: ADULTS, >50 YEARS, NO OTHER RISK FACTORS](#)

[TABLE 3: COMPARISON OF RECOMMENDATIONS FOR SCREENING FOR COLORECTAL CANCER: PEOPLE AT INCREASED RISK FOR COLORECTAL CANCER](#)

[TABLE 4: BENEFITS/HARMS OF SCREENING](#)

[Benefits of Screening](#)

[Harms of Screening](#)

[TABLE 5: EVIDENCE AND RECOMMENDATION RATING SCHEMES: REFERENCES SUPPORTING THE RECOMMENDATIONS](#)

[GUIDELINE CONTENT COMPARISON](#)

[Areas of Agreement](#)

[Areas of Differences](#)

INTRODUCTION:

A direct comparison of American Gastroenterological Association/American Society for Gastrointestinal Endoscopy/American College of Physicians/American College of Gastroenterology (AGA/ASGE/ACP/ACG), Finnish Medical Society Duodecim (FMS), University of Michigan Health System (UMHS), and U.S. Preventive Services Task Force (USPSTF) recommendations for colorectal cancer screening, among individuals of varying risk for developing colorectal cancer, is provided in the five tables below. This synthesis purposefully excludes recommendations for symptomatic individuals and the management of positive screening results.

[Table 1](#) presents the guidelines' scope, comparing the objectives, target population, intended users, and screening interventions discussed in each guideline. [Table 2](#) focuses on screening recommendations for asymptomatic individuals who are at average risk for colorectal cancer. Various screening interventions are presented along with recommendations regarding frequency and administration of screening tests where applicable. [Table 3](#) considers screening and surveillance recommendations for individuals at increased risk for colorectal cancer. [Table 4](#) compares the potential benefits and possible harms associated with screening. [Table 5](#) provides a comparison of the various evidence and recommendation rating schemes used by FMS, UMHS and USPSTF. It also includes citations for the references supporting recommendations, where applicable.

Following the content comparison, areas of agreement and differences among the guidelines are discussed. In general, the timing of the guideline with respect to available data is an important factor to consider when evaluating areas of differences among guidelines.

Abbreviations used in the text and table:

- ACG, American College of Gastroenterology
- ACP, American College of Physicians
- AGA, American Gastroenterological Association
- ASGE, American Society for Gastrointestinal Endoscopy
- CRC, colorectal cancer
- DCBE, double contrast barium enema
- DRE, digital rectal examination
- FAP, familial adenomatous polyposis
- FMS, Finnish Medical Society Duodecim
- FOBT, fecal occult blood testing
- HNPCC, hereditary nonpolyposis colorectal cancer
- TCE, total colon examination
- UMHS, University of Michigan Health System
- USPSTF, United States Preventive Services Task Force

TABLE 1: SCOPE
Objective

AGA/ASGE/ACP/ACG (2003)	<ul style="list-style-type: none"> To incorporate updated evidence into clinical practice recommendations To summarize new developments in the field and suggest how they should change practice
FMS (2005)	Evidence-Based Medicine Guidelines collect, summarize, and update the core clinical knowledge essential in general practice. The guidelines also describe the scientific evidence underlying the given recommendations.
UMHS (2004)	To implement an evidenced-based strategy for cancer screening in adults
USPSTF (2002)	<ul style="list-style-type: none"> To summarize the current recommendations on screening for CRC and the supporting evidence To update the 1996 recommendations contained in the Guide to Clinical Preventive Services, 2nd edition
Target Population	
AGA/ASGE/ACP/ACG (2003)	<ul style="list-style-type: none"> People in the United States (U.S.) at average risk for CRC (asymptomatic, age ≥ 50 years, no other risk factors) People in the U.S. at increased risk for CRC (history of adenomatous polyps or CRC; family history of colon cancer, an adenomatous polyp, familial adenomatous polyposis, or hereditary nonpolyposis CRC) <p>Note: People with symptoms or signs that suggest the presence of CRC or polyps fall outside the domain of screening and should be offered an appropriate diagnostic evaluation (see Table 2 in the original guideline document).</p>
FMS (2005)	<ul style="list-style-type: none"> Finland Asymptomatic persons with increased risk for colorectal cancer General population
UMHS (2004)	<ul style="list-style-type: none"> United States Adults, 18 years and older
USPSTF (2002)	<ul style="list-style-type: none"> United States

	<ul style="list-style-type: none"> Men and women 50 years of age or older
Intended Users	
AGA/ASGE/ACP/ACG (2003)	Physicians
FMS (2005)	Health Care Providers Physicians
UMHS (2004)	Physicians
USPSTF (2002)	Advanced Practice Nurses Allied Health Personnel Health Care Providers Nurses Physician Assistants Physicians
Screening Interventions Considered	
AGA/ASGE/ACP/ACG (2003)	<ol style="list-style-type: none"> 1. FOBT, guaiac-based and immunochemical technologies 2. Sigmoidoscopy 3. Combined FOBT and sigmoidoscopy 4. Colonoscopy 5. DCBE
FMS (2005)	<ol style="list-style-type: none"> 1. FOBT, guaiac-based 2. Colonoscopy
UMHS (2004)	<ol style="list-style-type: none"> 1. FOBT 2. Flexible sigmoidoscopy 3. Colonoscopy <p>Screening options considered but not recommended:</p> <ol style="list-style-type: none"> 1. Air or double-contrast barium enema 2. DRE 3. Stool deoxyribonucleic acid (DNA) test 4. Virtual colonoscopy <p>Note: This guideline also addresses interventions regarding breast cancer screening, prostate cancer screening and cervical cancer screening.</p>

USPSTF (2002)	<ol style="list-style-type: none"> 1. Home FOBT 2. Flexible sigmoidoscopy 3. The combination of home FOBT and flexible sigmoidoscopy 4. Colonoscopy 5. DCBE <p>Screening options considered but not recommended:</p> <ol style="list-style-type: none"> 1. DRE 2. Computed tomography colography
------------------	---

TABLE 2: COMPARISON OF RECOMMENDATIONS FOR SCREENING FOR COLORECTAL CANCER: ADULTS, \geq 50 YEARS, NO OTHER RISK FACTORS	
Choosing a Screening Test	
AGA/ASGE/ACP/ACG (2003)	Men and women at average risk should be offered screening for colorectal cancer and adenomatous polyps beginning at age 50 years. They should be offered options for screening, with information about the advantages and disadvantages associated with each approach, and should be given an opportunity to apply their own preferences in selecting how they should be screened.
FMS (2005)	No recommendations offered.
UMHS (2004)	<p>Recommended methods include: FOBT, flexible sigmoidoscopy, or colonoscopy. (DRE is not effective in screening for colorectal cancer.)</p> <p>Individualizing screening to offer the highest likelihood of compliance and the least intrusive option to the patient may be warranted. In addition to patient preference, other factors, such as age, comorbidities, and test availability may influence the choice of screening modality.</p>
USPSTF (2002)	Potential screening options for colorectal cancer include home fecal occult blood testing, flexible sigmoidoscopy, the combination of home fecal occult blood testing and flexible sigmoidoscopy, colonoscopy, and double-contrast barium enema. Each option has advantages

	<p>and disadvantages that may vary for individual patients and practice settings. The choice of specific screening strategy should be based on patient preferences, medical contraindications, patient adherence, and available resources for testing and follow-up. Clinicians should talk to patients about the benefits and potential harms associated with each option before selecting a screening strategy.</p>
Fecal Occult Blood Testing (FOBT)	
AGA/ASGE/ACP/ACG (2003)	<ul style="list-style-type: none"> • Offer yearly screening with FOBT using a guaiac-based test with dietary restriction or an immunochemical test without dietary restriction. • Two samples from each of 3 consecutive stools should be examined without rehydration.
FMS (2005)	<p>The results of large trials involving screening for faecal occult blood indicate a reduction in mortality from colorectal cancer (Towler et al., 2002) [A], but such screening results in colonoscopy being performed on a large proportion of the screened population. The cost-effectiveness of screening is controversial. Only about 50% of those invited can be expected to attend screening (Vernon, 1997; DARE, 1999) [B].</p>
UMHS (2004)	<p>Initiate: For average risk, asymptomatic patients, screening should begin at age 50.</p> <p>Average risk. FOBT: annually [A]</p>
USPSTF (2002)	<ul style="list-style-type: none"> • The USPSTF strongly recommends that clinicians screen men and women 50 years of age or older for colorectal cancer. Grade A recommendation. • The USPSTF found fair to good evidence that several screening methods are effective in reducing mortality from colorectal cancer. The USPSTF concluded that the benefits from screening substantially outweigh potential harms, but the quality of evidence, magnitude of benefit, and potential harms vary with each method. • There is good evidence that periodic FOBT reduces mortality from CRC. • Annual FOBT offers greater reductions in mortality rates than biennial screening but produces more false-positive results. • Proven methods of FOBT screening use guaiac-based test cards prepared at home by patients from three consecutive stool samples and

	forwarded to the clinician. Whether patients need to restrict their diet and avoid certain medications is not established. Rehydration of the specimens before testing increases the sensitivity of fecal occult blood testing but substantially increases the number of false-positive test results.
Flexible Sigmoidoscopy	
AGA/ASGE/ACP/ACG (2003)	Offer flexible sigmoidoscopy every 5 years.
FMS (2005)	No recommendations offered.
UMHS (2004)	Initiate: For average risk, asymptomatic patients, screening should begin at age 50. Average risk. Flexible sigmoidoscopy: every 5 years [A]
USPSTF (2002)	<ul style="list-style-type: none"> • The USPSTF strongly recommends that clinicians screen men and women 50 years of age or older for colorectal cancer. Grade A recommendation. • The USPSTF found fair to good evidence that several screening methods are effective in reducing mortality from colorectal cancer. The USPSTF concluded that the benefits from screening substantially outweigh potential harms, but the quality of evidence, magnitude of benefit, and potential harms vary with each method. • There is fair evidence that sigmoidoscopy alone or in combination with FOBT reduces mortality. • 5-year intervals have been recommended for flexible sigmoidoscopy; there is no direct evidence with which to determine the optimal interval. Case-control studies have suggested that sigmoidoscopy every 10 years may be as effective as sigmoidoscopy performed at shorter intervals.
Combined Fecal Occult Blood Testing and Flexible Sigmoidoscopy	
AGA/ASGE/ACP/ACG (2003)	Offer screening with FOBT every year combined with flexible sigmoidoscopy every 5 years. When both tests are performed, the FOBT should be done first.
FMS (2005)	No recommendations offered.

UMHS (2004)	<p>Initiate: For average risk, asymptomatic patients, screening should begin at age 50.</p> <p>Average risk: FOBT/flexible sigmoidoscopy: annually/every 5 years [B]</p>
USPSTF (2002)	<ul style="list-style-type: none"> • The USPSTF strongly recommends that clinicians screen men and women 50 years of age or older for colorectal cancer. Grade A recommendation. • The USPSTF found fair to good evidence that several screening methods are effective in reducing mortality from colorectal cancer. The USPSTF concluded that the benefits from screening substantially outweigh potential harms, but the quality of evidence, magnitude of benefit, and potential harms vary with each method. • There is fair evidence that sigmoidoscopy alone or in combination with FOBT reduces mortality. • The combination of fecal occult blood testing and sigmoidoscopy may detect more cancers and more large polyps than either test alone, but the additional benefits and potential harms of combining the two tests are uncertain. In general, the FOBT should precede sigmoidoscopy because a positive test result is an indication for colonoscopy, obviating the need for sigmoidoscopy.
Digital Rectal Examination (DRE)	
AGA/ASGE/ACP/ACG (2003)	Screening with DRE was not considered.
FMS (2005)	Screening with DRE was not considered.
UMHS (2004)	DRE is not effective in screening for colorectal cancer.
USPSTF (2002)	<ul style="list-style-type: none"> • The USPSTF strongly recommends that clinicians screen men and women 50 years of age or older for colorectal cancer. Grade A recommendation. • The USPSTF found fair to good evidence that several screening methods are effective in reducing mortality from colorectal cancer. The USPSTF concluded that the benefits from screening substantially outweigh potential harms, but the quality of evidence, magnitude of benefit, and potential harms vary with each method. • Neither DRE nor the testing of a single stool

	specimen obtained during digital rectal examination is recommended as an adequate screening strategy for colorectal cancer.
Barium Enema	
AGA/ASGE/ACP/ACG (2003)	Offer DCBE every 5 years.
FMS (2005)	No recommendations offered.
UMHS (2004)	Initiate: For average risk, asymptomatic patients, screening should begin at age 50. Average risk: Air or double-contrast barium enema (acceptable modality but not recommended): every 5 years [B].
USPSTF (2002)	<ul style="list-style-type: none"> • The USPSTF strongly recommends that clinicians screen men and women 50 years of age or older for colorectal cancer. Grade A recommendation. • The USPSTF found fair to good evidence that several screening methods are effective in reducing mortality from colorectal cancer. The USPSTF concluded that the benefits from screening substantially outweigh potential harms, but the quality of evidence, magnitude of benefit, and potential harms vary with each method. • DCBE offers an alternative means of whole-bowel examination, but it is less sensitive than colonoscopy, and there is no direct evidence that it is effective in reducing mortality rates. • Five year intervals have been recommended for DCBE screening but there is no direct evidence with which to determine the optimal interval.
Colonoscopy	
AGA/ASGE/ACP/ACG (2003)	Offer colonoscopy every 10 years.
FMS (2005)	The use of colonoscopy for screening of asymptomatic individuals is indicated only in cases with marked familial susceptibility to cancer, or if an adenoma has earlier been removed endoscopically.
UMHS	Initiate: For average risk, asymptomatic patients,

(2004)	<p>screening should begin at age 50.</p> <p>Average risk: Colonoscopy: every 10 years [B].</p>
USPSTF (2002)	<ul style="list-style-type: none"> • The USPSTF strongly recommends that clinicians screen men and women 50 years of age or older for colorectal cancer. Grade A recommendation. • The USPSTF found fair to good evidence that several screening methods are effective in reducing mortality from colorectal cancer. The USPSTF concluded that the benefits from screening substantially outweigh potential harms, but the quality of evidence, magnitude of benefit, and potential harms vary with each method. • The USPSTF did not find direct evidence that screening colonoscopy is effective in reducing CRC mortality; efficacy of colonoscopy is supported by its integral role in trials of fecal occult blood testing, extrapolation from sigmoidoscopy studies, limited case-control evidence, and the ability of colonoscopy to inspect the proximal colon. • It is unclear whether the increased accuracy of colonoscopy compared with alternative screening methods (for example, the identification of lesions that FOBT and flexible sigmoidoscopy would not detect) offsets the procedure's additional complications, inconvenience, and costs. • A 10-year interval has been recommended for colonoscopy on the basis of evidence regarding the natural history of adenomatous polyps.

TABLE 3: COMPARISON OF RECOMMENDATIONS FOR SCREENING FOR COLORECTAL CANCER: PEOPLE AT INCREASED RISK FOR COLORECTAL CANCER	
People with Family History of Colorectal Cancer	
AGA/ASGE/ACP/ACG (2003)	<p>People with a first-degree relative (parent, sibling, or child) with colon cancer or adenomatous polyps diagnosed at age <60 years or 2 first-degree relatives diagnosed with colorectal cancer at any age should be advised to have screening colonoscopy starting at age 40 years or 10 years younger than the earliest diagnosis in their family, whichever comes first, and repeated every 5 years (see Table 3 in the original</p>

	<p>guideline document).</p> <p>People with a first-degree relative with colon cancer or adenomatous polyp diagnosed at age ≥ 60 years or 2 second-degree relatives with colorectal cancer should be advised to be screened as average risk persons, but beginning at age 40 years.</p> <p>People with 1 second-degree relative (grandparent, aunt, or uncle) or third-degree relative (great-grandparent or cousin) with colorectal cancer should be advised to be screened as average risk persons.</p>
FMS (2005)	The use of colonoscopy for screening of asymptomatic individuals is indicated only in cases with marked familial susceptibility to cancer, or if an adenoma has earlier been removed endoscopically.
UMHS (2004)	<ul style="list-style-type: none"> • Persons who have one second-degree (includes grandparents, aunts, and uncles) or any third-degree relative (includes great-grandparents and cousins) with colorectal cancer should be screened in the same way as average risk individuals.* • Persons who have a first degree relative (includes parents, siblings, and children) affected with colorectal cancer or adenomatous polyp at age ≥ 60 years, or 2 second-degree relatives affected with colorectal cancer should be screened in the same way as average risk individuals, but starting at age 40 years.* • Persons who have two or more first-degree relatives with colon cancer, or a single first-degree relative with colon cancer or adenomatous polyps diagnosed at an age < 60 years should be screened with a colonoscopy every 5 years, beginning at age 40 years or 10 years younger than the earliest diagnosis in the family, whichever comes first.* <p>*From the American Gastroenterological Association, American Society for Gastrointestinal Endoscopy, American College of Physicians, American College of Gastroenterology (AGA/ASGE/ACP/ACG). Colorectal cancer screening and surveillance: clinical guidelines and rationale-update based on new evidence. Gastroenterology 2003 Feb; 124(2): 544-60.</p>
USPSTF (2002)	In persons at higher risk (for example, those with a first-degree relative who receives a diagnosis with CRC before 60 years of age), initiating screening at an earlier age is reasonable.
People with a Family History of Familial Adenomatous Polyposis	

AGA/ASGE/ACP/ACG (2003)	People who have a genetic diagnosis of familial adenomatous polyposis (FAP), or are at risk of having FAP but genetic testing has not been performed or is not feasible, should have annual sigmoidoscopy, beginning at age 10 to 12 years, to determine if they are expressing the genetic abnormality. Genetic testing should be considered in patients with FAP who have relatives at risk. Genetic counseling should guide genetic testing and considerations of colectomy.
FMS (2005)	The use of colonoscopy for screening of asymptomatic individuals is indicated only in cases with marked familial susceptibility to cancer or if an adenoma has earlier been removed endoscopically.
UMHS (2004)	<ul style="list-style-type: none"> • Persons who have a first degree relative (includes parents, siblings, and children) affected with colon cancer or adenomatous polyps at age ≥ 60 years should be screened in the same way as average risk individuals, but starting at age 40 years.* • Persons who have two or more first-degree relatives with colon cancer, or a single first-degree relative with colon cancer or adenomatous polyps diagnosed at an age < 60 years should be screened with a colonoscopy every 5 years, beginning at age 40 years or 10 years younger than the earliest diagnosis in the family, whichever comes first* • Persons who are gene carriers or at risk for familial adenomatous polyposis (includes the subcategories of familial adenomatous polyposis, Gardner syndrome, some Turcot syndrome families, and attenuated adenomatous polyposis coli [AAPC]) should be screened with a sigmoidoscopy annually, beginning at age 10 to 12 years. (For patients with AAPC, colonoscopy should be used instead of sigmoidoscopy because of the preponderance of proximal colonic adenomas. Colonoscopy screening in AAPC should probably begin in the late teens or early 20s.)* <p>*From the American Gastroenterological Association, American Society for Gastrointestinal Endoscopy, American College of Physicians, American College of Gastroenterology (AGA/ASGE/ACP/ACG). Colorectal cancer screening and surveillance: clinical guidelines and rationale-update based on new evidence. Gastroenterology 2003 Feb; 124(2):544-60.</p>
USPSTF (2002)	Expert guidelines exist for screening very high-risk patients, including those with a history suggestive of familial polyposis or hereditary nonpolyposis CRC or those with a personal history of ulcerative colitis. Early screening with colonoscopy may be appropriate, and

	genetic counseling or testing may be indicated for patients with genetic syndromes.
People with a Family History of Hereditary Nonpolyposis Colorectal Cancer (HNPCC)	
AGA/ASGE/ACP/ACG (2003)	People with a genetic or clinical diagnosis of HNPCC or who are at increased risk for HNPCC should have colonoscopy every 1 to 2 years beginning at age 20 to 25 years, or 10 years earlier than the youngest age of colon cancer diagnosis in the family--whichever comes first. Genetic testing for HNPCC should be offered to first-degree relatives of persons with a known inherited mismatch repair (MMR) gene mutation. It should also be offered when the family mutation is not already known, but 1 of the first 3 of the modified Bethesda Criteria is met (see Table 5 in the original guideline document).
FMS (2005)	The use of colonoscopy for screening of asymptomatic individuals is indicated only in cases with marked familial susceptibility to cancer or if an adenoma has earlier been removed endoscopically.
UMHS (2004)	<p>Persons who are gene carriers or pancolitis at risk for HNPCC should be screened with a colonoscopy every 1 to 2 years, beginning at age 20 to 25 years or 10 years younger than the earliest case in the family, whichever comes first.*</p> <p>*From the American Gastroenterological Association, American Society for Gastrointestinal Endoscopy, American College of Physicians, American College of Gastroenterology (AGA/ASGE/ACP/ACG). Colorectal cancer screening and surveillance: clinical guidelines and rationale-update based on new evidence. Gastroenterology 2003 Feb; 124(2): 544-60.</p>
USPSTF (2002)	Expert guidelines exist for screening very high-risk patients, including those with a history suggestive of familial polyposis or hereditary nonpolyposis CRC or those with a personal history of ulcerative colitis. Early screening with colonoscopy may be appropriate, and genetic counseling or testing may be indicated for patients with genetic syndromes.
People with a History of Adenomatous Polyps	
AGA/ASGE/ACP/ACG (2003)	Patients who have had 1 or more adenomatous polyps removed at colonoscopy should be managed according to the findings on that colonoscopy. Patients who have had numerous adenomas, a malignant adenoma (with

	<p>invasive cancer), a large sessile adenoma, or an incomplete colonoscopy should have a short interval follow-up colonoscopy based on clinical judgment. Patients who have advanced or multiple adenomas (≥ 3) should have their first follow-up colonoscopy in 3 years. Patients who have 1 or 2 small (< 1 cm) tubular adenomas should have their first follow-up colonoscopy at 5 years. It is not unreasonable, given available evidence, to choose even longer intervals. However, the evidence is still evolving. Future evidence may clarify the intervals more precisely.</p> <p>The timing of the subsequent colonoscopy should depend on the pathology and number of adenomas detected at follow-up colonoscopy. For example, if the first follow-up colonoscopy is normal or only 1 or 2 small (< 1 cm) tubular adenomas are found, the next colonoscopy can be in 5 years.</p>
FMS (2005)	<ul style="list-style-type: none"> • The use of colonoscopy for screening of asymptomatic individuals is indicated if an adenoma has earlier been removed endoscopically. • Follow-up after the initial investigations is not indicated in persons with a single small tubular adenoma in the rectum, or in patients above 75 years of age. • Individuals with a history of one large adenoma or several adenomas of any type should undergo screening colonoscopy at 3- to 5-year intervals.
UMHS (2004)	<p>Persons who have a history of adenomatous polyps, for example:</p> <ul style="list-style-type: none"> • 1 or 2 small (< 1 cm) tubular adenomas • Advanced or multiple adenomas (≥ 3) <p>Manage according to the findings and clinical judgment, for example:</p> <ul style="list-style-type: none"> • First follow-up colonoscopy at 5 years • First follow-up colonoscopy in 3 years. <p>Timing of subsequent colonoscopy depends on findings at follow-up.*</p> <p>*From the American Gastroenterological Association, American Society for Gastrointestinal Endoscopy, American College of Physicians, American College of Gastroenterology (AGA/ASGE/ACP/ACG). Colorectal cancer screening and surveillance: clinical guidelines and rationale-update based on new evidence.</p>

	Gastroenterology 2003 Feb; 124(2): 544-60.
USPSTF (2002)	Expert guidelines exist for screening very high-risk patients, including those with a history suggestive of familial polyposis or hereditary nonpolyposis CRC, or those with a personal history of ulcerative colitis. Early screening with colonoscopy may be appropriate, and genetic counseling or testing may be indicated for patients with genetic syndromes.
People with a History of Colorectal Cancer	
AGA/ASGE/ACP/ACG (2003)	Patients with a colon cancer that has been resected with curative intent should have a colonoscopy around the time of initial diagnosis to rule out synchronous neoplasms. If the colon is obstructed preoperatively, colonoscopy can be performed approximately 6 months after surgery. If this or a complete preoperative examination is normal, subsequent colonoscopy should be offered after 3 years, and then, if normal, every 5 years.
FMS (2005)	No recommendations offered.
UMHS (2004)	<p>History of CRC: After colonoscopy to rule out synchronous neoplasms and resection with curative intent, first follow-up colonoscopy after 3 years, and then, if normal, every 5 years.</p> <p>*From the American Gastroenterological Association, American Society for Gastrointestinal Endoscopy, American College of Physicians, American College of Gastroenterology (AGA/ASGE/ACP/ACG). Colorectal cancer screening and surveillance: clinical guidelines and rationale-update based on new evidence. Gastroenterology 2003 Feb; 124(2): 544-60.</p>
USPSTF (2002)	People with a history of CRC are beyond the scope of this guideline.
People with Inflammatory Bowel Disease	
AGA/ASGE/ACP/ACG (2003)	In patients with long-standing, extensive inflammatory bowel disease, surveillance colonoscopy with systematic biopsies should be considered. This applies to both ulcerative colitis and Crohn's colitis because the cancer risk is similar in both diseases.
FMS (2005)	No recommendations offered.

UMHS (2004)	<p>Inflammatory bowel disease (ulcerative colitis, Crohn's colitis): In patients with long-standing, extensive inflammatory bowel disease (ulcerative colitis, Crohn's colitis), surveillance colonoscopy with systematic biopsies should be considered.*</p> <p>*From the American Gastroenterological Association, American Society for Gastrointestinal Endoscopy, American College of Physicians, American College of Gastroenterology (AGA/ASGE/ACP/ACG). Colorectal cancer screening and surveillance: clinical guidelines and rationale-update based on new evidence. Gastroenterology 2003 Feb; 124(2):544-60.</p>
USPSTF (2002)	<p>Expert guidelines exist for screening very high-risk patients, including those with a history suggestive of familial polyposis or hereditary nonpolyposis CRC, or those with a personal history of ulcerative colitis. Early screening with colonoscopy may be appropriate, and genetic counseling or testing may be indicated for patients with genetic syndromes.</p>

TABLE 4: BENEFITS/HARMS OF SCREENING	
Benefits of Screening	
AGA/ASGE/ACP/ACG (2003)	<ul style="list-style-type: none"> Increased rates of appropriate and timely colorectal cancer screening based on patient and physician collaboration Improved physician and patient understanding of the rationale and evidence supporting colorectal cancer screening options (refer to the rationale section in the original guideline document for the relative effectiveness of each screening test) Reduced morbidity and mortality due to colorectal cancer Reduced health care costs
FMS (2005)	<p>Screening may help detect colorectal cancer and reduce the incidence of or mortality from colorectal cancer.</p>
UMHS (2004)	<p>Early detection and treatment may avert future cancer-related illness.</p>
USPSTF (2002)	<ul style="list-style-type: none"> Fecal Occult Blood Testing (FOBT). There is good evidence that periodic FOBT reduces mortality from CRC. Annual FOBT offers greater reductions in mortality rates than biennial screening but

	<p>produces more false-positive results. Three randomized controlled trials (RCTs), all using the Hemoccult® test kit, show reductions in risk of death from colorectal cancer from 15% to 33% from periodic fecal occult blood test screening. Two European trials, which randomized patients prior to agreement to participate and used biennial screening and unrehydrated test cards, found 15% to 18% reductions in mortality. In a U.S. study, which randomized volunteers and used rehydrated test cards, colorectal cancer mortality after 18 years of follow-up was 33% lower among persons advised to undergo annual fecal occult blood test than among controls who received usual care (9.46 versus 14.09 deaths per 1,000 patients screened); biennial screening reduced mortality by 21%. A fourth trial conducted in Sweden has not reported final mortality results, but no significant mortality reduction was reported after 2 rounds of rehydrated testing (relative risk [RR], 0.88; 95% confidence interval [CI], 0.69 - 1.12).</p> <ul style="list-style-type: none"> • Sigmoidoscopy. Current evidence of the effectiveness of sigmoidoscopy is limited to several well-designed case-control studies, but 2 ongoing randomized controlled trials of screening with flexible sigmoidoscopy are expected to report results within 5 years. A case-control study in a large health plan that had implemented rigid sigmoidoscopy screening suggested that screening reduced the risk of death from cancers within reach of the rigid sigmoidoscope by 59%. A second case-control study in which 75% of the examinations were performed with a flexible instrument found similar protection. • Fecal Occult Blood Testing and Sigmoidoscopy. No randomized controlled trials have examined whether combining fecal occult blood testing and sigmoidoscopy would lower mortality or morbidity more than either test alone. In a nonrandomized, controlled study involving more than 12,000 first-time attendees at a preventive-health clinic screened using rigid sigmoidoscopy, the addition of fecal occult blood testing detected more cancers on initial screening than sigmoidoscopy alone, but mortality after 9 years was not significantly lower (0.36 per 1,000 patient-years in patients receiving both tests versus 0.63 per 1,000 patient years in controls; $p = 0.11$). Whether results are generalizable to flexible sigmoidoscopy is uncertain. • Double Contrast Barium Enema. No trial has examined the ability of screening barium enema to
--	--

	<p>reduce the incidence or mortality from colorectal cancer.</p> <ul style="list-style-type: none"> Colonoscopy. The effectiveness of colonoscopy to prevent colorectal cancer or mortality has not been tested in a randomized clinical trial. The National Polyp Study, a randomized trial of different intervals of surveillance after polypectomy, estimated that 76% to 90% of cancers could be prevented by regular colonoscopic surveillance exams. These results should be interpreted with caution, however, because they are based on historical controls, and trial participants had more complete polyp removal than may occur in the screening setting. A single case-control study suggests that colonoscopy is associated with lower incidence of colon cancer (odds ratio = 0.47; 95% CI, 0.37-0.58) and lower mortality from colorectal cancer (odds ratio = 0.43; 95% CI, 0.30-0.63). Slightly greater benefits of colonoscopy have been predicted in models that project benefits based on sensitivity of screening and rates of polyp progression. Computed tomography colography. No studies have evaluated the effectiveness of computed tomography colography in reducing morbidity or mortality from colorectal cancer.
Harms of Screening	
AGA/ASGE/ACP/ACG (2003)	<ul style="list-style-type: none"> Currently available tests for fecal occult blood fail to detect many polyps and some cancers. Also, most people who test positive will not have colorectal neoplasia (have a false positive test result) and thus will undergo the discomfort, cost, and risk of colonoscopy without benefit. Colonoscopy involves greater cost, risk, and inconvenience to the patient than other screening tests, and not all examinations visualize the entire colon. Genetic testing can have psychological effects and subject persons with positive tests to the risks of discrimination. Therefore, it should only be performed after genetic counseling of patients and parents of children.
FMS (2005)	<p>Harmful effects of screening include:</p> <ul style="list-style-type: none"> The physical complications of colonoscopy (perforation or haemorrhage)

	<ul style="list-style-type: none"> • Disruption to lifestyle • Stress and discomfort of testing and investigations • The anxiety caused by false positive screening tests • False negative tests. Because the sensitivity and specificity of faecal occult blood are rather poor, a negative result does not exclude colorectal cancer in a symptomatic patient.
UMHS (2004)	No harmful effects discussed
USPSTF (2002)	<p>Fecal occult blood test has few potential harms but false-positive tests can lead to invasive procedures such as colonoscopy. Sigmoidoscopy can, in rare instances, lead to bowel perforation (1 to 2 per 10,000 examinations). In a study of 1,235 screening sigmoidoscopies, adverse effects included pain (14%), anxiety, bleeding (3%), gas or flatus (25%), but no perforations. One patient died from complications after surgery to remove a severely dysplastic adenoma. A survey of barium enema experience reported that important complications of any type occurred in 1 in 10,000 examinations; perforation occurred in 1 in 25,000 examinations; death in 1 in 55,000 examinations.</p> <p>Screening colonoscopy poses higher risks than fecal occult blood test or sigmoidoscopy, both because it is a more invasive procedure and because generally it is used with conscious sedation, which may lead to complications. The risks of colonoscopy depend on whether it is used simply for screening and diagnosis, or whether it is also used for therapeutic procedures (e.g., removal of polyps). In two studies of screening colonoscopies in more than 5,000 patients, 0.2% to 0.3% had major complications during or immediately after the procedures, the most common being bleeding requiring hospitalization or emergency care.</p> <p>Risks are higher in therapeutic procedures (e.g., when polypectomy is performed) than in diagnostic or screening procedures. Rates of perforation for diagnostic procedures in 16 published studies ranged from 0.03% to 0.61%. There are few data on bleeding complications but one study reported no bleeding events in 250 patients.</p> <p>The complication rates for therapeutic procedures were higher in some studies: 0.07% to 0.72% for perforations and 0.2% to 2.67% for bleeding. Death</p>

	<p>was rare (between 1 in 16,000 to 1 in 27,000) and more likely in symptomatic patients with acute problems or those with comorbid conditions. The mortality rate as a result of screening is likely to be on the lower end of this range. Complication rates could increase, however, if widespread adoption of colonoscopy leads to more procedures by less skilled endoscopists. Data are lacking on complications of computed tomography colography.</p> <p>Patient Preferences and Adherence</p> <p>Some patients report that they find the fecal occult blood test unpleasant or difficult to perform, but 50% to 70% of patients will complete fecal occult blood test when advised to by a clinician. A reminder system can increase adherence rates by an average of 14%. Studies conducted in primary care settings have found rates of adherence for sigmoidoscopy to be 25% to 50% for the initial test, but there are no data on adherence to repeat examinations. When given information about screening options and offered the choice of fecal occult blood test alone, sigmoidoscopy alone, or both tests together, most patients in an academic internal medicine clinic preferred both tests or fecal occult blood test alone; only 8% to 13% preferred sigmoidoscopy alone. However, patient adherence to combined testing is lower than it is for sigmoidoscopy or fecal occult blood test alone. Patients' acceptance of barium enema screening has not been evaluated.</p> <p>Studies examining the relative discomfort of barium enema and colonoscopy have produced inconsistent results. In one study of patients in a population with considerable previous screening experience, 38% preferred colonoscopy to other methods. The acceptability and feasibility of computed tomography colography have not been examined.</p>
--	---

TABLE 5: EVIDENCE AND RECOMMENDATION RATING SCHEMES; REFERENCES SUPPORTING THE RECOMMENDATIONS	
Rating Scheme	
FMS (2005)	<p>Levels of Evidence</p> <p>A. Strong research-based evidence. Several relevant, high-quality</p>

	<p>scientific studies with homogeneous results.</p> <p>B. Moderate research-based evidence. At least one relevant, high-quality study or multiple adequate studies.</p> <p>C. Limited research-based evidence. At least one adequate scientific study.</p> <p>D. No scientific evidence. Expert panel evaluation of other information.</p> <p>References Supporting the Recommendations</p> <ul style="list-style-type: none"> • The database of abstracts of reviews of effectiveness (University of York), DARE-971223. In: Cochrane Library [database online]. Issue 4. Oxford: Update Software; 1999 • Towler BP, Irwig L, Glasziou P, Weller D, Kewenter J. Screening for colorectal cancer using the faecal occult blood test, Hemoccult [CD001216]. In: Cochrane Database of Systematic Reviews, Cochrane Library [database online]. Issue 2. Oxford: Update Software; 2002 • Vernon SW. Participation in colorectal cancer screening: a review. J Natl Cancer Inst 1997 Oct 1;89(19):1406-22. [214 references]
UMHS (2004)	<p>Levels of evidence reflect the best available literature in support of an intervention or test:</p> <p>A. Randomized controlled trials</p> <p>B. Controlled trials, no randomization</p> <p>C. Observational trials</p> <p>D. Opinion of expert panel</p> <p>References Supporting the Recommendations</p> <p>American Gastroenterological Association, American Society for Gastrointestinal Endoscopy, American College of Physicians, American College of Gastroenterology (AGA/ASGE/ACP/ACG). Colorectal cancer screening and surveillance: clinical guidelines and rationale-update based on new evidence. Gastroenterology 2003 Feb;124(2):544-60.</p>
USPSTF (2002)	<p>The U.S. Preventive Services Task Force (USPSTF) grades the quality of the overall evidence on a 3-point scale (good, fair, or poor).</p> <p>Good</p> <p>Evidence includes consistent results from well-designed, well-conducted studies in representative populations that directly assess effects on health outcomes.</p> <p>Fair</p> <p>Evidence is sufficient to determine effects on health outcomes, but the strength of the evidence is limited by the number, quality, or consistency of the individual studies; generalizability to routine</p>

	<p>practice; or indirect nature of evidence on health outcomes.</p> <p>Poor Evidence is insufficient to assess the effects on health outcomes because of limited number of power of studies, important flaws in their design or conduct, gaps in the chain of evidence, or lack of information on important health outcomes.</p> <p>The USPSTF grades its recommendations according to one of five classifications (A, B, C, D, or I), reflecting the strength of evidence and magnitude of net benefit (benefits minus harms).</p> <p>A The USPSTF strongly recommends that clinicians routinely provide [the service] to eligible patients. (The USPSTF found good evidence that [the service] improves important health outcomes and concludes that benefits substantially outweigh harms.)</p> <p>B The USPSTF recommends that clinicians routinely provide [the service] to eligible patients. (The USPSTF found at least fair evidence that [the service] improves health outcomes and concludes that benefits outweigh harms.)</p> <p>C The USPSTF makes no recommendation for or against routine provision of [the service]. (The USPSTF found at least fair evidence that [the service] can improve health outcomes but concludes that the balance of benefits and harms is too close to justify a general recommendation.)</p> <p>D The USPSTF recommends against routinely providing [the service] to asymptomatic patients. (The USPSTF found at least fair evidence that [the service] is ineffective or that harms outweigh benefits.)</p> <p>I The USPSTF concludes that the evidence is insufficient to recommend for or against routinely providing [the service]. (Evidence that [the service] is effective is lacking, of poor quality, or conflicting and the balance of benefits and harms cannot be determined.)</p>
--	--

GUIDELINE CONTENT COMPARISON

The American Gastroenterological Association in collaboration with the American Society for Gastrointestinal Endoscopy, American College of Physicians, and American College of Gastroenterology (AGA/ASGE/ACP/ACG), the Finnish Medical Society Duodecim (FMS), the University of Michigan Health System (UMHS), and

the U.S. Preventive Services Task Force (USPSTF) present recommendations for CRC screening in people at average risk (asymptomatic, age ≥ 50 years, no other risk factors) and provide explicit reasoning behind their judgments. Also, AGA/ASGE/ACP/ACG, and FMS present recommendations for asymptomatic adults with some degree of increased risk of developing CRC. USPSTF and UMHS refer to expert guidelines from medical specialty organizations (AGA/ASGE/ACP/ACG, for example) for individuals at risk.

Areas of Agreement

Screening Adults of Average Risk

All guideline developer organizations represented in this synthesis recommend screening for colorectal cancer in average risk, asymptomatic adults. The three guideline developers located in North America, AGA/ASGE/ACP/ACG, UMHS, and USPSTF provide an age at which screening should begin (≥ 50 years); FMS does not designate a starting age. The three guideline developers located in North America also recommend screening, utilizing one of several acceptable screening tests such as fecal occult blood testing (FOBT) or flexible sigmoidoscopy. These three groups present two or more acceptable screening options and do not explicitly recommend one screening test over another citing a lack of solid evidence to do so. FMS only considers FOBT for population-based screening in its recommendations (although it makes no clear recommendations for it); In discussing the rationale for FOBT, UMHS acknowledges that clear evidence for reduced CRC mortality exists with a mass FOBT screening program, but further notes that this screening modality has come under criticism due to its low sensitivity and specificity, low patient compliance, and the possibility that it does little more than randomly assign subjects to receive colonoscopy.

Choosing a Screening Intervention for Adults of Average Risk

The three guideline developer organizations presenting recommendations for how to choose a screening test, AGA/ASGE/ACP/ACG, UMHS, and USPSTF, agree that patients should be involved, to some degree, in selecting a screening intervention. Each of these three organizations agrees the advantages and disadvantages of the various screening options should be shared with the patient. AGA/ASGE/ACP/ACG recommends candidates should then have the opportunity to select how they will be screened. USPSTF and UMHS state what should be considered when making the choice, one item being patient preference.

Acceptable Screening Interventions for Adults of Average Risk

DRE

All guideline developer organizations represented in this synthesis directly or indirectly acknowledge that the DRE is not an acceptable screening intervention.

FOBT, Sigmoidoscopy, FOBT + Sigmoidoscopy, Colonoscopy, Barium Enema

Three guideline developer organizations, AGA/ASGE/ACP/ACG, UMHS, and USPSTF recognize FOBT, sigmoidoscopy, combination of FOBT and sigmoidoscopy,

and colonoscopy as acceptable screening interventions for use in asymptomatic adults of average risk. These organizations acknowledge that the option of total colon examination (TCE) by colonoscopy or barium enema has not been supported by randomized controlled trials and that support for its use comes from indirect evidence of benefit and efficacy. UMHS notes that air or double-contrast barium enema is an acceptable modality, but does not recommend it. FMS only considered FOBT for screening asymptomatic adults of average risk (and colonoscopy for screening asymptomatic adults at increased risk). All organizations recognize that a positive FOBT result requires diagnostic follow-up.

Acceptable Screening Interventions for Adults of Increased Risk

Surveillance with Colonoscopy

There is general agreement among the guideline developers who provide screening recommendations for individuals at risk for developing CRC that colonoscopy is the most appropriate screening intervention for people with a history of adenomatous polyps, CRC, or inflammatory bowel disease.

Genetic Counseling and Genetic Testing

AGA/ASGE/ACP/ACG, and USPSTF recommend genetic counseling followed by genetic testing for individuals with FAP and HNPCC. Genetic counseling and genetic testing are not interventions considered by FMS or UMHS.

Familial Susceptibility

The guidelines are in general agreement regarding screening recommendations for people with a family history of CRC. AGA/ASGE/ACP/ACG, UMHS, and USPSTF recommend increased surveillance or earlier screening for these individuals. FMS recommends colonoscopy for persons with marked familial susceptibility but does not state the age at which to begin or how frequently.

Areas of Differences

Acceptable Screening Interventions for Adults of Average Risk

FOBT: Rehydration of Cards, Dietary Restrictions, Newer Technology

There are several differences regarding the recommended procedure for FOBT. AGA/ASGE/ACP/ACG, FMS, and USPSTF recommend use of screening cards. AGA/ASGE/ACP/ACG strongly recommends against rehydration of the cards. AGA/ASGE/ACP/ACG notes that although rehydration increases sensitivity, it results in increased false-positive rates. USPSTF acknowledges these two effects of rehydration on test results but does not specifically recommend against it. UMHS does not discuss the recommended procedure for FOBT but recognizes that FOBT screening protocols vary.

AGA/ASGE/ACP/ACG recommends use of dietary restrictions when the newer, more sensitive, guaiac-based FOBTs are used but not when the new immunochemical FOBTs are performed. AGA/ASGE/ACP/ACG cited a systematic

review of 3 trials which found no improvement in positivity rates or change in compliance rates noting that the older, less sensitive guaiac-based tests were used in the trials. AGA/ASGE/ACP/ACG further notes that dietary restriction does affect the performance of the more sensitive guaiac-based FOBTs recently introduced into clinical practice. USPSTF states the value of dietary restrictions is not established. Dietary restrictions in relationship to FOBTs are not discussed by UMHS and FMS.

AGA/ASGE/ACP/ACG is the only guideline developer to specifically recommend use of immunochemical FOBTs in practice.

DCBE and Colonoscopy -- Screening Frequency

Differences are also noted in recommendations for screening frequency for double-contrast barium enema (DCBE) and colonoscopy. AGA/ASGE/ACP/ACG recommends DCBE every 5 years. USPSTF cites the lack of evidence to make a recommendation regarding screening intervals. UMHS refers to the AGA/ASGE/ACPA/ACG recommendation for DCBE screening every 5 years, but does not recommend, only stating the need for more observational studies of barium enema in literature.

AGA/ASGE/ACP/ACG recommends colonoscopy every 10 years, and USPSTF does not offer recommendations for screening interval stating there is insufficient evidence to recommend for or against routine screening with colonoscopy. UMHS refers to the to the AGA/ASGE/ACPA/ACG recommendation for colonoscopy screening every 10 years, but suggests that studies are limited.

This Synthesis was originally prepared by ECRI on June 7, 1998, and has been updated and revised on a number of occasions since that time. It has been reviewed by each of the guideline developers that are represented. It was updated in December 2006, to withdraw CTHPHC guidelines following their removal from the NGC Web site. This Synthesis was updated again on May 15, 2007 to withdraw ACS guidelines following their removal from the NGC Web site.

Internet citation: National Guideline Clearinghouse (NGC). Guideline synthesis: Screening for colorectal cancer. In: National Guideline Clearinghouse (NGC) [website]. Rockville (MD): 1998 Jun 7 (updated 2007 May). [cited YYYY Mon DD]. Available: <http://www.guideline.gov>.

© 1998-2007 National Guideline Clearinghouse

Date Modified: 5/14/2007

